IFNG and colitis: The results demonstrated that IFN-γ treatment could enhance the capacity of exosomes derived from MSCs to attenuate mice colitis phenotype via upregulating the level of miR-125a and miR-125b, which directly targeting on the 3′-UTR of Stat3 to repress Th17 cells and the inflammation.